USPTO serial 99172024
ECTRUDYS
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- ELLINGER FATHY, JESSICA M
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ECTRUDYS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Rockville, MD, US
Rockville, MD, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
William R. Samuels
William R. Samuels Cole-Frieman & Mallon, LLP201 California street, Suite 350San Francisco, CA 94111United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biological preparations for medical use in the treatment of genetic diseases and disorders, and muscle disorders, namely, Duchenne muscular dystrophy; Pharmaceutical preparations, namely, recombinant adeno-associated viral (rAAV) vectors for use in gene therapy; Pharmaceutical preparations for the treatment of genetic diseases and disorders, and muscle disorders, namely, Duchenne muscular dystrophy; Clinical medical reagents for use in gene therapy; Therapeutic pharmaceutical compositions that include recombinant adeno-associated viral (rAAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy; Pharmaceutical preparations containing adeno-associated viral (AAV) vectors and nucleic acids for a system delivering genes to biological cells for use in the treatment of genetic diseases and disorders, namely, Duchenne muscular dystrophy; Gene therapy preparation for medical use containing genetic materials for sustained protein expression, namely, microdystrophin expression | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 20, 2026 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 20, 2026 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 16, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 21, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 21, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 15, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 23, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 23, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| May 6, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 6, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 6, 2025 | NWAP | NEW APPLICATION ENTERED | — |